Promising anti-IL-6 therapy for atherosclerosis
- PMID: 34040184
- DOI: 10.1038/s41569-021-00575-8
Promising anti-IL-6 therapy for atherosclerosis
Comment on
-
IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial.Lancet. 2021 May 29;397(10289):2060-2069. doi: 10.1016/S0140-6736(21)00520-1. Epub 2021 May 17. Lancet. 2021. PMID: 34015342 Clinical Trial.
References
Original article
-
- Ridker, P. M. et al. IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet https://doi.org/10.1016/S0140-6736(21)00520-1 (2021) - DOI - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
